Log In
BCIQ
Print this Print this
 

Transdur-bupivacaine, bupivacaine (Eladur) (DUR-843)

  Manage Alerts
Collapse Summary General Information
Company Durect Corp.
DescriptionTransdermal pain patch
Molecular Target Sodium channel
Mechanism of ActionNa channel blocker
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationPain
Indication DetailsTreat chronic low back pain; Treat pain associated with post-herpetic neuralgia (PHN); Treat persistent pain
Regulatory Designation
PartnerImpax Laboratories Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$63.0M

$2.0M

$61.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/20/2014

$63.0M

$2.0M

$61.0M

Get a free BioCentury trial today